Comparison between moexipril and atenolol in obese postmenopausal women with hypertension

Maturitas

Volumn 30, Issue 1, 1998, Pages 69-77

  Stimpel, M ^a   Koch, B ^a   Weber, M A ^b  

^a Schwarz Pharma AG   (Germany)

^b BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Atenolol; Hypertension; Moexipril; Postmenopausal women

Indexed keywords

ATENOLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; INSULIN; LOW DENSITY LIPOPROTEIN; MOEXIPRIL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ASTHENIA; CARBOHYDRATE METABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; INSULIN BLOOD LEVEL; LEG EDEMA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MAXILLA SINUSITIS; MULTICENTER STUDY; NAUSEA; OBESITY; PAIN; PHARYNGITIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SITTING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VERTIGO;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATENOLOL; FEMALE; HUMANS; HYPERTENSION; ISOQUINOLINES; LIPIDS; MIDDLE AGED; OBESITY; POSTMENOPAUSE; TETRAHYDROISOQUINOLINES;

EID: 0032552657     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(98)00037-1     Document Type: Article

References (31)

1. Sutherland J., Castle C., Friedman R. Clinical review. Hypertension: current management strategies. J Am Board Family Pract. 7(3):1994;202-217.
2. Sacks F.M., Gerhard M., Walsh B.W. Sex hormones, lipoproteins, and vascular reactivity. Curr Opin Lipidol. 6(3):1995;161-166.
3. Gillmer M.D. Mechanism of action/effects of androgens on lipid metabolism. Int J Fertil. 37(suppl 2):1992;83-92.
4. Barrett-Connor E., Bush T. Estrogen and coronary heart disease in women. J Am Med Assoc. 265:1991;1861-1867.
5. Kannel W.B. Metabolic risk factors for coronary heart disease in women: Perspective from the Framingham study. Am Heart J. 114:1987;413-419.
6. Castelli W.P. Cardiovascular disease in women. Am J Obstet Gynecol. 158:1988;1553-1560.
7. Godsland I.F., Wynn V., Crook D., Miller N.E. Special report: sex, plasma lipoproteins, and atherosclerosis; prevailing assumptions and outstanding questions. Am Heart J. 114(6):1987;1467-1503.
8. Ramsay L.E., Yeo W.W., Jackson P.R. Metabolic effects of diuretics. Cardiology. 84(Suppl 2):1994;48-56.
9. Black H.R. Metabolic considerations in the choice of therapy for the patient with hypertension. Am Heart J. 121:1991;707-715.
10. Fogari F., Zoppi A., Malamani G.D., Marasi G., Vanasta A., Villa G. Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients. Br J Clin Pharmacol. 39:1995;471-476.
11. Lardinois C.K., Neuman S.L. The effects of antihypertensive agents on serum lipids and lipoproteins. Arch Intern Med. 148:1988;1280-1288.
12. Grimm R.H., Leon A.S., Hunninghake D.B., Lenz K., Hannan P., Blackburn H. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients. Ann Intern Med. 94:1981;7-11.
13. Black H.R. The coronary artery disease paradox: the role of hyperinsulinemia and insulin resistance and implications for therapy. J Cardiovasc Pharmacol. 15(suppl 5):1990;S26-38.
14. MacMahon S.W., Cutler J.A., Furberg C.D., Payne G.H. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Prog Cardiovasc Dis. 29:1986;99-118.
15. Middeke M., Richter W.O., Schwandt P., Beck B., Holzgreve H. Normalization of lipid metabolism after withdrawal from antihypertensive long-term therapy with beta blockers and diuretics. Arteriosclerosis. 10(1):1990;145-147.
16. Burris J.F. The expanding role of angiotensin converting enzyme inhibitors in the management of hypertension. J Clin Pharmacol. 35(4):1995;337-342.
17. Physicians' Desk Reference, 50th ed. Montvale, NJ: Medical Economics Company, 1996.
18. Black H.R. Metabolic considerations in the choice of therapy for the patient with hypertension. Am Heart J. 121:1991;707-715.
19. Risler T., Kramer B., Müller G.A., Seipel L. Was ist gesichert in der Therapie mit Angiotensin-converting-enzyme (ACE) Hemmern? (What is the scientific basis for treatment with angiotensin-converting enzyme (ACE) inhibitors?). Internist. 30:1989;790-796.
20. Weinberger M.H. Angiotensin converting enzyme inhibitors enhance the antihypertensive efficacy of diuretics and blunt or prevent adverse metabolic effects. J Cardiovasc Pharmacol. 13(suppl 3):1989;S1-S4.
21. Middeke M. Lipidstoffwechsel und Hypertonie. Epidemiologische, pathogenetische und therapeutische Aspekte. Corvas. 5:1991;209-216.
22. Dickstein K.et al. Comparison of the efficacy of three dose levels of moexipril versus placebo as add-on therapy to hydrochlorothiazide in patients with moderate hypertension. J Cardiovasc Pharmacol. 24:1994;247-255.
23. Morice A.H., Brown M.J., Higenbottam T. Cough associated with angiotensin converting enzyme inhibition. J Cardiovasc Pharmacol. 13(suppl 3):1989;S59-S62.
24. Girard M. The safety of angiotensin-converting enzyme (ACE) inhibitors in moderate hypertension. Adverse Drug React. Toxicol. Rev. 10:1991;169-185.
25. Parish R.C., Miller L.J. Adverse effects of angiotensin converting enzyme (ACE) inhibitors. Drug Saf. 7:1992;14-31.
26. Persson B., Stimpel M. Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients. Eur J Clin Pharmacol. 50:1996;259-264.
27. Abernethy D.R., Fox A.A.L., Stimpel M. Moexipril in the treatment of mild to moderate essential hypertension: comparison with sustained-release verapamil. J Clin Pharmacol. 35:1995;794-799.
28. Leonetti G., Cuspidi C. Choosing the right ACE inhibitor. A guide to selection. Drugs. 49:1995;516-535.
29. De Quattro V. Comparison of benazepril and other antihypertensive agents alone and in combination with the diuretic hydrochlorothiazide. Clin Cardiol. 14(Suppl 4):1991;28-32.
30. Plosker G.L., Sorkin E.M. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders. Drugs. 48:1992;227-252.
31. Vlasses P.H., Potmensch H.H., Swanson B.N., Irvin J.D., Lee R.B., Koplin J.R., Ferguson R.K. Comparative antihypertensive effects of enalapril maleate and hydrochlorothiazide, alone and in combination. J Clin Pharmacol. 23:1983;227-233.